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Abstract
Background: Fascioliasis is an emerging zoonotic disease of considerable veterinary and public health importance.
Triclabendazole is the only available drug for treatment. Laboratory studies have documented promising fasciocidal
properties of the artemisinins (e.g., artemether).
Methodology: We carried out two exploratory phase-2 trials to assess the efficacy and safety of oral artemether
administered at (i) 6680 mg over 3 consecutive days, and (ii) 36200 mg within 24 h in 36 Fasciola-infected individuals in
Egypt. Efficacy was determined by cure rate (CR) and egg reduction rate (ERR) based on multiple Kato-Katz thick smears
before and after drug administration. Patients who remained Fasciola-positive following artemether dosing were treated
with single 10 mg/kg oral triclabendazole. In case of treatment failure, triclabendazole was re-administered at 20 mg/kg in
two divided doses.
Principal Findings: CRs achieved with 6680 mg and 36200 mg artemether were 35% and 6%, respectively. The
corresponding ERRs were 63% and nil, respectively. Artemether was well tolerated. A high efficacy was observed with
triclabendazole administered at 10 mg/kg (16 patients; CR: 67%, ERR: 94%) and 20 mg/kg (4 patients; CR: 75%, ERR: 96%).
Conclusions/Significance: Artemether, administered at malaria treatment regimens, shows no or only little effect against
fascioliasis, and hence does not represent an alternative to triclabendazole. The role of artemether and other artemisinin
derivatives as partner drug in combination chemotherapy remains to be elucidated.
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Introduction
Fascioliasis, a zoonotic disease caused by a liver fluke infection
of the species Fasciola hepatica and F. gigantica, is of considerable
veterinary and public health importance [1,2]. Owing to global
changes, infections with Fasciola spp. appear to be emerging or re-
emerging in several parts of the world [1]. An estimated 91 million
people are at risk of fascioliasis, whereas the estimated number of
infections shows a large range from 2.4 to 17 million [3]. Severe
clinical complications in the chronic phase of a Fasciola infection
include cholangitis, cholecystitis, jaundice, and biliary colic [1,4].
In Egypt, fascioliasis is an important clinical problem,
particularly among school-aged children living in rural areas of
the Nile Delta [5,6]. Prevalence rates of Fasciola infections have
been reduced in recent years, explained by control measures put
forth by the Egyptian governorates, including triclabendazole
administration [6]. Indeed, chemotherapy with triclabendazole, a
member of the benzimidazole family of anthelmintics, is the
current mainstay for morbidity control of fascioliasis [7]. It should
be noted, however that triclabendazole is often difficult to obtain,
since it is currently registered in only four countries for human
treatment [7]. In addition, resistant fluke populations have been
reported from several countries [7–9]. Unfortunately, no vaccine is
currently available for prevention of fascioliasis [10].
There is a need to develop new fasciocidal drugs. Several studies
have documented that the artemisinins (e.g., artemether and
artesunate), which have become the most important antimalarial
drugs, particularly when deployed as artemisinin-based combina-
tion therapy (ACT) [11], also possess schistosomicidal [12] and
fasciocidal activities [13]. Regarding fascioliasis, complete elimina-
tion of worms was achieved in rats experimentally infected with
adult F. hepatica when artesunate and artemether were administered
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at single oral doses (400 and 200 mg/kg, respectively) 8 weeks
postinfection [14]. Severe tegumental changes and death of flukes
occurred when Fasciola spp. were incubated with an artemisinin
derivative (50–100 mg/ml) in vitro [14–17]. Artesunate and arte-
mether, given by the intramuscular route, yielded high egg and
worm burden reductions in natural F. hepatica infections in sheep
[18,19]. Finally, a study in 100 Vietnamese patients has shown that
artesunate might also play a role in the treatment of acute
fascioliasis, as patients treated with artesunate were significantly
more likely to be free of abdominal pain when compared to
triclabendazole-treated patients [20].
The aim of the present study was to assess the efficacy and safety
of oral artemether, adhering to two different malaria treatment
regimens [21,22], in patients with a chronic Fasciola spp. infection.
The study was carried out in a Fasciola-endemic area of Egypt,
where Schistosoma mansoni co-exists, but malaria is absent.
Methods
Ethics Statement
Ethical clearance was obtained from the Theodor Bilharz
Research Institute (Giza, Egypt), the Ministry of Health and
Population (Cairo, Egypt), and the Ethics Committee of Basel,
Switzerland (EKBB, reference no. 54/07). The trial is registered
with Current Controlled Trials (reference no. ISRCTN10372301).
Written informed consent was obtained from eligible study
participants or parents/legal guardians from individuals aged
below 16 years.
Study Design, Sample Size, and Outcome Measures
The study was designed as an interventional, open-label, non-
randomized, proof-of-concept trial, consisting of two separate
single-arm studies, to evaluate the efficacy and safety of two
artemether regimens in the treatment of asymptomatic Fasciola-
infected patients. Twenty individuals were assigned to each study,
following recommendations for pilot studies of at least 12 patients
per treatment [23] and sufficient number of patients who might
not comply to follow-up.
The primary end points were cure rate (CR, defined as
percentage of patients who became Fasciola egg-negative after
treatment, who were egg-positive at study enrollment) and egg
reduction rate (ERR, defined as reduction of geometric mean
(GM) egg output after treatment divided by the GM of the same
individuals before treatment, multiplied by a factor 100) of Fasciola
infection, 28 days after the final dosing. Incidence of adverse
events, monitored up to 2 days after the final dosing, was used as
secondary outcome measure.
Paticipants who remained Fasciola positive following artemether
treatment were orally treated with a single 10 mg/kg dose of
triclabendazole. Efficacy of triclabendazole was determined in the
frame of the second intervention study. Patients who were still
found with Fasciola eggs in their stool following 10 mg/kg
triclabendazole were treated with 20 mg/kg triclabendazole in
two divided doses.
Study Area and Population
Study 1 was carried out between April and July 2007 in El-
Haddad El-Bahary village, Behera governorate, north-east of
Delta. El-Haddad El-Bahary village is s a typical rural setting, with
canals fed from the Nile River and no access to the Mediterra-
nean. The total population in the village is 8144.
Study 2 was conducted between August 2008 and May 2010 in
Abis village, located south-west of Alexandria. It comprises 10 sub-
villages, with an estimated total population of 35,000. Abis village
is fed by water canals drawn from the Nile River, with no access to
the Mediterranean.
Treatment
Artemether, formulated as 40 mg capsules (study 1) and 50 mg
tablets (study 2) was purchased from Kunming Pharmaceutical
Cooperation (ArtemidineH; Kunming, People’s Republic of
China). The following two treatment schemes were investigated:
(i) 6680 mg over 3 consecutive days (study 1) and (ii) 36200 mg
within 24 h (study 2). Treatment was supervised by a physician
with date and precise time of drug administration recorded.
Patients were observed for 1 h to ensure retention of medication.
In case of vomiting or any treatment-related adverse events, a
second dose of artemether was administered.
Triclabendazole (EgatenH 250 mg tablets, scored tablets) was
the product of Novartis (Basel, Switzerland). Patients who failed to
become Fasciola egg-negative following artemether administration
received 10 mg/kg triclabendazole. The triclabendazole dosage,
according to the patients’ weight, was calculated in half-tablet
increments with a maximum of 2.5 tablets (625 mg). In case of
triclabendazole treatment failures (assessed in study 2), patients
were provided two doses of 10 mg/kg of triclabendazole given on
subsequent days according to manufacturer’s instructions.
Study Flow
Several weeks before conducting a parasitological baseline
survey, the health directorate of Beheira (study 1) and Alexandria
governorate (study 2) were informed about the objectives,
procedures, and potential risks and benefits. After written
informed consent was obtained, participants were asked to provide
a stool sample in order to screen for the presence of F. hepatica
and/or F. gigantica eggs. Stool collection containers were labeled
with patient’s name and a unique identifier (ID). Filled containters
were transfered to a laboratory for diagnostic work-up. Two
additional stool samples were collected on consecutive days among
participants who were found with Fasciola eggs in their feces. In
addition, a blood sample was collected before drug administration
to examine hematologic parameters, liver, and kidney functions.
Author Summary
Fasciola hepatica and F. gigantica are two liver flukes that
parasitize herbivorous large size mammals (e.g., sheep and
cattle), as well as humans. A single drug is available to treat
infections with Fasciola flukes, namely, triclabendazole.
Recently, laboratory studies and clinical trials in sheep and
humans suffering from acute fascioliasis have shown that
artesunate and artemether (drugs that are widely used
against malaria) also show activity against fascioliasis.
Hence, we were motivated to assess the efficacy and safety
of oral artemether in patients with chronic Fasciola
infections. The study was carried out in Egypt and
artemether administered according to two different
malaria treatment regimens. Cure rates observed with
6680 mg and 36200 mg artemether were 35% and 6%,
respectively. In addition, high efficacy was observed when
triclabendazole, the current drug of choice against human
fascioliasis, was administered to patients remaining
Fasciola positive following artemether treatment. Conclud-
ing, monotherapy with artemether does not represent an
alternative to triclabendazole against fascioliasis, but its
role in combination chemotherapy regimen remains to be
investigated.
Artemether in the Treatment of Fascioliasis
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At enrollment a full clinical examination was carried out to
assess participants’ general health status. Exclusion criteria were: (i)
age below 5 years, (ii) pregnancy, (iii) major systemic illnesses (e.g.,
history of chronic illness such as cancer, diabetes, hypertension,
chronic heart, liver or renal disease, severe liver disease of other
etiology), and (iv) recent history of anthelmintic treatment (e.g.,
albendazole, bithionol, dehydroemetine, mebendazole, praziquan-
tel, and triclabendazole taken within the past 4 weeks). Patients
meeting our inclusion criteria were treated with artemether, which
was administered over 3 consecutive days (study 1) or within 24 h
(study 2).
Adverse events were monitored on each treatment day and for
24–48 h following the final dosing. Participants were asked to
report any potential drug-related signs and symptoms using a
standardized questionnaire. Full clinical examinations were
performed on all participants. Adverse events were graded (i.e.,
mild, moderate, severe, and serious) and recorded. Therapy was
offered to patients presenting with adverse events, as judged by the
study physician.
Five and 28 days posttreatment, blood samples were collected
for clinical chemistry analyses. The final parasitological assessment
started on day 28 posttreatment: stool samples were obtained from
all study participants over 5 consecutive days. Patients found with
Fasciola eggs in their stool following artemether administration
were treated with 10 mg/kg triclabendazole. In study 2, stool
samples were collected from triclabendazole-treated patients 28
days posttreatment over 3 consecutive days and CRs and ERRs
were determined. Those patients who remained Fasciola positive
were retreated with a double dose of triclabendazole (20 mg/kg
given 24 h apart) [24] and efficacy (CRs and ERRs) was assessed
28 days posttreatment, on the basis of three stool samples. In both
groups of triclabendazole-treated patients, liver and renal function
and hematological parameters were determined pre- and post-
treatment (5 and 28 days after drug administration).
Laboratory Procedures
For detection and quantification of Fasciola eggs, all stool
samples were processed shortly after collection using the Kato-
Katz technique [25]. From each stool sample, 3–6 thick smears
were prepared on microscope slides. The slides were transported
in enumerated boxes to the Theodor Bilharz Research Institute
and examined within a maximum of 48 h. The presence of S.
mansoni and soil-transmitted helminths (i.e., Ascaris lumbricoides and
Trichuris trichiura) was also determined and recorded for each
participant individually. Each slide was examined independently
in a blind manner by two microscopists. For quality control,
several slides were re-examined by a senior staff. For confirmation
of Fasciola and other helminth eggs, at baseline the merthiolate-
iodine formaldehyde (MIF) concentration technique [26] was
employed for one stool sample per participant. Briefly, 2.35 ml of
stock MIF solution was added to at least about 0.5 g of each stool
sample in a 15 ml centrifuge tube, closed with a rubber stopper,
and placed in a refrigerator for subsequent examination. On the
next morning 0.15 ml of Lugol’s iodine solution was added to each
tube. After centrifugation, the upper layers of sedimented feces
containing parasite material were examined under a microscope.
Laboratory investigations of blood included total leukocyte
count, hemoglobin, eosinophilic count, alanine transpeptidase
(ALT), aspartate transpeptidase (AST), alkaline phosphatase
(ALP), gamma glutamyl transpeptidase (GGT), total serum
bilirubin, blood urea, and serum creatinine. The blood specimens
were collected into gel serum tubes (for clinical chemistry
variables) and EDTA tubes (for hematology variables). Blood
specimens collected into gel tubes were centrifuged at 1800–2000 g
for 10–15 min. All blood specimens were analyzed on the day of
collection.
Statistical Analysis
Data were entered using EpiData version 6.04 (Epidata
Association; Odense, Denmark). CR was calculated as proportion
of individuals excreting Fasciola eggs before treatment and absence
of eggs at study end. To determine infection intensity, the number
of Fasciola eggs per Kato-Katz thick smear (41.7 mg of stool) was
multiplied by a factor 24 to obtain eggs per gram of stool (EPG).
Fecal egg counts (FECs) of multiple slides per individual were
averaged, using the arithmetric mean. To calculate the reduction
in infection intensity, individual egg counts were logarithmically
transformed (log (count + 1) and the GM expressed as the
antilogarithm of the mean. The ERR was calculated as [1 - GM
FEC after treatment divided by GM FEC at admission multiplied
by a factor 100]. Although infection intensity thresholds are
currently lacking for infections with Fasciola [27], we classified
infections into two groups: (i) light (1–99 EPG) and (ii) moderate/
heavy ($100 EPG). Of note, a threshold of 100 EPG is also used
to distringuish between light and moderate (100–399 EPG) and
heavy ($400 EPG) S. mansoni infection [27]. Fisher’s exact test,
including 95% confidence intervals (CI), and Mann-Whitney U
test were used to compare the outcome of both studies (2-sided P
values) assuming no difference in population or sensitivity of the
parasite strain. The 2-tailed paired t-test and the Kruskal-Wallis
tests were employed to compare the clinical parameters before and
after treatment.
Results
Baseline Characteristics
Of 584 villagers and 51 school-aged children screened in El-
Haddad El-Bahary village (study 1), 22 individuals were found
Fasciola-positive. Two patients were excluded (pregnancy, n= 1;
age below 5 years, n = 1). Twenty patients (10 females, 10 males;
aged 5–70 years with a mean of 24 years) were included in study 1
(Table 1).
In the second study, 631 individuals were examined and 19
Fasciola-positive subjects were identified. Of these, 17 patients (10
females, 7 males; aged 5–26 years, with a mean of 14 years)
(Table 1) were included in the study. However, two of the positive
cases were excluded because the initial diagnosis by the Ministry of
Health and Population could not been confirmed.
The baseline GM Fasciola FECs in the two studies were 28.3
EPG and 29.1 EPG (Table 2). Twenty-six individuals were
classified as lightly infected (1–99 EPG), whereas 10 individuals
had a moderate/heavy infection ($100 EPG). Ten participants
were concurrently infected with Fasciola spp. and S. mansoni, and
one patient was identified with a double infection of Fasciola spp.
and Hymenolepis nana.
Efficacy of Artemether
Data from all patients were included in the analysis, as no
patient was lost to follow-up (per-protocol analysis). CRs achieved
with 6680 mg and 36200 mg artemether were 35% and 6%,
respectively (Table 2). Fisher’s exact test showed a statistical
difference between the CRs obtained with the different treatment
schedules (P = 0.048; 95% CI: 0.002–1.15). None of the patients
characterized by an infection intensity of 100 EPG and above was
cured after artemether administration regardless of the treatment
regimen, while CRs documented in patients with a light Fasciola
infection were 54% (6680 mg artemether) and 8% (36200 mg
artemether) (CRs of light infections were significantly higher in
Artemether in the Treatment of Fascioliasis
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study 1 compared to study 2; P = 0.013; 95% CI: 0.001–0.77).
Treatment with artemether over 3 consecutive days resulted in
ERRs of 63% (67% for light infections and 55% for infections
$100 EPG). The individual pretreatment and posttreatment FECs
are presented in Figure 1. No effect on FECs were observed when
artemether was administered on a single treatment day with the
exception of a very low ERR of 6% among patients with an
infection intensity $100 EPG. The overall ERR between the two
studies differed significantly (P,0.001).
In each of the two studies, five patients were co-infected with S.
mansoni. At treatment follow-up, three out of the five patients in
each study were recorded egg-free (CR: 60%).
Efficacy of Triclabendazole
Sixteen patients who were still found Fasciola-positive after
treatment with 36200 mg artemether were administered a single
10 mg/kg oral dose of triclabendazole. CR and ERR were 69%
and 94%, respectively; significantly higher than CR (P,0.001;
95% CI: 3.19–1605.7) and ERR (P,0.001) observed following
treatment with 36200 mg artemether. The infection intensity did
not influence the treatment outcome (data not shown). Four out of
five patients who were still passing Fasciola eggs following a single
triclabendazole dose were provided a double dose of triclabenda-
zole and the respective CR and ERR were 75% and 96%.
Safety Assessment
Clinical chemistry variables. There were no noteworthy
effects of artemether on the liver enzymes and renal function
parameters, with the exception of a statistically significant increase
in GGT 5 days after the final dosing of artemether (6680 mg)
(Table 3). Following treatment with 36200 mg artemether, GGT
values were lower 28 days posttreatment when compared to
baseline values. ALT values significantly decreased between the
first and second follow-up time point. Finally, the values for ALP
were above the reference range before and after treatment with
artemether given over 3 consecutive days. Hematological
Table 1. Demographic baseline characteristics of 57 Fasciola-infected patients at inclusion.
Treatment
Characteristics
Artemether
(6680 mg)
Artemether
(36200 mg)
Triclabendazole
(10 mg/kg)
Triclabendazole
(20 mg/kg)
No. of patients treated 20 17 16 4
Males/females 10/10 7/10 6/10 2/2
Mean (SD) age, years 24.4 (21.5) 13.9 (5.8) 14.4 (5.8) 16.3 (2.5)
Mean (SD) weight, kg 43.9 (23.1) 49.5 (24.4) 55.4 (26.2) 66.3 (19.8)
Range of actual total dose (mean), mg/kg 6–26.7 (14.4) 8.3–31.6 (15.8) n.d. n.d.
n.d., not determined; SD, standard deviation.
doi:10.1371/journal.pntd.0001285.t001
Table 2. Effect of artemether administered at two different regimens to patients infected with Fasciola spp.
Treatment Fasciola spp. S. mansoni
Infection
intensity
No. of
patients
treated
No. of
patients
cured (%)
Pre-treatment
GM Fasciola
egg count
(EPG)
Post-
treatment
GM Fasciola
egg count
(EPG) ERR (%)
No. of
patients
treated
No. of
patients
cured (%) ERR (%)
Study 1
(6680 mg artemether)
All infections 20* 7 (35)** 28.3 10.4 63** 5 3 (60) 59
1–99 EPG 13 7 (54)** 12.6 4.2 67
$100 EPG 6 0 161.0 72.7 55
Study 2
(36200 mg artemether)
All infections 17 1 (6) 29.1 32.0 0 5 3 (60) n.d.
1–99 EPG 13 1 (8) 18.8 21.7 0
$100 EPG 4 0 119.6 113.0 5.5
Follow-up: triclabendazole
(10 mg/kg)
16 11 (69)** 32.0 2.0 94***
Follow-up: triclabendazole
(20 mg/kg, split dose)
4 3 (75) 39.6 1.5 96
EPG, eggs per gram of stool; ERR, egg reduction rate; GM, geometric mean; n.d., not determined.
*One patient was diagnosed positive with MIF only, hence no quantitative egg count is available at baseline.
**CR significantly different (P,0.05) from study 2 (36200 mg artemether).
***ERR highly significantly different (P,0.001) from study 2 (36200 mg artemether).
doi:10.1371/journal.pntd.0001285.t002
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parameters were not found to significantly differ from baseline
values, with the exception of hemoglobin, which was significantly
increased 28 days posttreatment with 6680 mg artemether.
The comparison between pre- and posttreatment values of liver
and renal function and hematological parameters showed no
significant differences following administration of triclabendazole
(10 and 20 mg/kg) (Table 4) apart from slight variations in
bilirubin and hemoglobin levels, which were slightly lower 7 days
posttreatment, compared to baseline and the second follow-up 28
days posttreatment.
Adverse events. Both artemether regimens were well
tolerated and no participant required special medical follow-up.
As summarized in Table 5, adverse events included abdominal
pain, fatigue, headache, vomiting, and diarrhea. Overall, 42 mild
and two moderate episodes of adverse events were reported when
artemether was given on 3 consecutive days. A slightly higher
number of adverse events was documented (n= 58) in patients
receiving artemether on a single day. However, all of these were
mild. The frequency of adverse events was similar among the two
treatment regimens, with the exception of headache and fever,
Figure 1. Pretreatment and posttreatment Fasciola egg counts in patients following two artemether regimens. Study was carried out in
Egypt and Fasciola-infected individuals were treated with either 6680 mg artemether (study 1) or 36200 mg artemether (study 2).
doi:10.1371/journal.pntd.0001285.g001
Table 3. Liver and renal function and hematological parameters pre- and posttreatment with artemether.
Parameter
Reference
range Study 1 (6680 mg artemether) Study 2 (36200 mg artemether)
Day of analysis Day of analysis
Pretreatment
day 0 (mean ±
SD)
Post-treatment
day 7 (mean ±
SD)
Post-treatment
day 28 (mean ±
SD)
Pretreatment
day 0 (mean ±
SD)
Posttreatment
day 5 (mean ±
SD)
Posttreatment
day 28 (mean ±
SD)
Alkaline phosphatase
(ALP) (IU/L)
30–120 162.1 (17.3) 163.4 (16.1) 161.1 (17.1) 65.8 (30.2) 63.8 (28.8) 61.3 (29.8)
Alanine transaminase
(ALT) (IU/L)
9–60 4.8 (0.6) 4.1 (0.4) 5.2 (0.5) 3.4 (4.6) 3.2 (2.2) 2.0 (1.0)**
Aspartate transaminase
(AST) (IU/L)
10–40 10.0 (0.3) 10.2 (0.4) 13.2 (2.1) 3.4 (2.7) 3.8 (4.3) 3.3 (2.5)
Gamma glutamyl
transpeptidase (GGT)
(IU/L)
0–51 10.7 (1.3) 12.2 (1.3)* 10.8 (1.4)** 8.0 (2.4) 7.3 (1.7) 6.4 (2.3)*
Bilirubin (mg/dl) 0.2–1.2 0.4 (0.1) 0.4 (0.1) 0.3 (0.03) 0.4 (0.1) 0.4 (0.1) 0.4 (0.1)
Urea (mg/dl) 12–48 29.0 (2.0) 29.7 (1.3) 28.8 (1.1) 35.2 (5.6) 35.2 (5.6) 34.6 (6.0)
Creatinine (mg/dl) 0.6–1.3 0.7 (0.03) 0.8 (0.04) 0.7 (0.03) 0.9 (0.3) 0.9 (0.2) 0.8 (0.1)
Eosinophils (%) 0–6 3.3 (0.4) 4.0 (0.4) 3.4 (0.4) 3.4 (1.9) 4.3 (2.8) 4.3 (2.8)
Hemoglobin (g/dl) 11.5–17.5 10.4 (0.3) 10.45 (0.3) 11.17 (0.2)*,** 13.6 (1.2) 13.4 (1.4) 13.0 (1.1)
Total leucocytes (mm3) 3900–10,000 6300 (179) 6253 (181) 6028 (195) 6010 (976) 6055 (1110) 6421 (874)
*Statistically significant difference from baseline (p,0.05).
**Statistically significant difference between first and second follow-up survey.
doi:10.1371/journal.pntd.0001285.t003
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Table 4. Liver and renal function and hematological parameters pre- and posttreatment with triclabendazole.
Parameter
Reference
range 10 mg/kg triclabendazole (n =16) 20 mg/kg triclabendazole (n =4)
Day of analysis Day of analysis
Pretreatment
day 0 (mean ±
SD)
Post-treatment
day 5 (mean ±
SD)
Post-treatment
day 28 (mean ±
SD)
Pretreatment
day 0 (mean ±
SD)
Post-treatment
day 5 (mean ±
SD)
Post-
treatment day
28 (mean ±
SD)
Alkaline phosphatase
(ALP) (IU/l)
30–120 133.7 (38.8) 137.3 (39.9) 135.8 (37.7) 111.0 (65.1) 106.4 (59.2) 99.5 (32.2)
Alanine transaminase
(ALT) (IU/l)
9–60 10.9 (2.3) 16.0 (11.4) 11.9 (2.5) 18.3 (3.2) 19.3 (8.1) 20.5 (9.3)
Aspartate transaminase
(AST) (IU/l)
10–40 10.6 (3.9) 19.6 (23.2) 13.1 (3.0) 23.5 (10.4) 29.3 (13.7) 29.3 (8.7)
Gamma glutamyl
transpeptidase (GGT) (IU/l)
0–51 7.0 (1.4) 8.3 (2.6) 7.7 (1.8) 7.2 (1.1) 9.4 (3.3) 9.4 (3.3)
Bilirubin (mg/dl) 0.2–1.2 0.6 (0.2) 0.4 (0.3)* 0.6 (0.2)** 0.4 (0.1) 0.6 (0.3) 0.6 (0.1)
Urea (mg/dl) 12–48 37.9 (11–0) 35.2 (12.6) 34.7 (6.6) 23.8 (2.0) 18.1 (6.3) 22.2 (2.7)
Creatinine (mg/dl) 0.6–1.3 0.8 (0.2) 0.7 (0.2) 0.8 (0.1) 0.9 (0.3) 1.1 (0.4) 0.9 (0.2)
Eosinophils (%) 0–6 4.5 (2.5) 3.3 (1.5) 3.5 (1.2) 3.8 (1.0) 3.5 (1.0) 4.0 (0.8)
Hemoglobin (g/dl) 11.5–17.5 12.8 (1.8) 11.3 (1.1)* 12.5 (1.3)** 13.5 (0.6) 13.3 (0.8) 12.9 (0.6)
Total leucocytes (mm3) 3900–10,000 6356 (951) 5950 (1074) 6707 (918) 5300 (902) 5900 (1320) 6350 (661)
*Statistically significant difference from baseline (p,0.05).
**Statistically significant difference between first and second follow-up survey.
doi:10.1371/journal.pntd.0001285.t004
Table 5. Treatment related adverse events observed in patients receiving artemether.
Treatment Adverse event Grading No. of adverse events (%)
Study 1 (6680 mg
artemether) (n = 20)
Examination point (hours post-treatment)
24 48 72 96 120
Abdominal pain Mild 0 6 (30) 1 (5) 7 (35) 5 (25)
Moderate 0 1 (5) 0 0 0
Fatigue Mild 0 4 (20) 1 (5) 1 (5) 0
Moderate 0 0 0 0 0
Headache Mild 0 1 (5) 1 (5) 3 (15) 0
Moderate 0 0 0 0 0
Diarrhea Mild 0 0 5 (25) 5 (25) 0
Moderate 0 1 (5) 0 0 0
Nausea Mild 0 0 0 0 0
Moderate 0 0 0 0 0
Vomiting Mild 1 (5) 1 (5) 0 0 0
Moderate 0 0 0 0 0
Study 2 (36200 mg
artemether) (n = 17)
Morning Mid day Evening 96 h
Abdominal pain Mild 1 (5) 1 (5) 4 (21) 6 (32)
Fatigue Mild 0 0 0 4 (21)
Headache Mild 3 (16) 0 3 (16) 13 (69)
Diarrhea Mild 0 0 1 (5) 2 (11)
Nausea Mild 0 0 0 3 (16)
Vomiting Mild 0 0 0 4 (21)
Fever Mild 0 0 0 6 (32)
Dizziness Mild 3 (16) 0 3 (16) 1 (5)
doi:10.1371/journal.pntd.0001285.t005
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which were more commonly reported in the second study (single
treatment day). Importantly though, adverse events were also
present prior to treatment and some of them occurred only 96 h
posttreatment, suggesting that they might not have been
treatment-related.
Abdominal pain was more often observed after treatment with
triclabendazole (Table 6) than after artemether regimens.
Headache and dizziness were other commonly observed adverse
events. However, many of the symptoms might have been disease-
rather than treatment-related, as they were already reported
before drug administration.
Discussion
While the veterinary importance of fascioliasis cannot be
overemphasized, this zoonotic disease is also of considerable and
growing public health importance, yet it often remains neglected.
A major challenge is that treatment is restricted to a single drug,
i.e., triclabendazole, which is registered for human use only in
Ecuador, Egypt, France, and Venezuela [7]. Results from a study
carried out in Vietnam raised some hope for an alternative;
artesunate administered to patients with symptomatic fascioliasis
pointed to a potential role of the artemisinins against fascioliasis.
Indeed, the authors concluded that it is worthwhile to investigate
this drug class in more detail, including additional clinical trials
[20]. We now present the first results with artemether in the
treatment of chronic fascioliasis in two epidemiological settings of
Egypt. Artemether (monotherapy) was administered following the
dosing regimen of a commonly used ACT, the 6-dose regimen of
artemether-lumefantrine [21], and a previously employed 3-dose
malaria treatment schedule administered on a single day [22].
Egypt was selected because of the known fascioliasis endemicity,
Table 6. Treatment-related adverse events observed in patients receiving triclabendazole.
Treatment Adverse event Grading No. of adverse events (%)
Examination point (hours posttreatment)
24 48 72
Triclabendazole (10 mg/kg) (n = 16) Abdominal pain Mild 0 8 (50) 8 (50)
Moderate 0 1 (6.3) 3 (18.8)
Fatigue Mild 0 0 1 (6.3)
Moderate 0 0 0
Headache Mild 0 5 (31.3) 5 (31.3)
Moderate 0 0 1 (6.3)
Diarrhea Mild 0 0 4 (25)
Moderate 0 0 1 (6.3)
Nausea Mild 0 0 0
Moderate 0 0 0
Vomiting Mild 0 2 (12.5) 2 (12.5)
Moderate 0 0 0
Fever Mild 0 0 1 (6.3)
Moderate 0 2 (12.5) 0
Dizziness Mild 0 10 (62.5) 4 (25)
Moderate 0 0 0
Triclabendazole (20 mg/kg) (n = 4) Abdominal pain Mild 0 4 2
Moderate 0 0 0
Fatigue Mild 0 2 (50) 0
Moderate 0 0 0
Headache Mild 3 (75) 2 (50) 1 (25)
Moderate 0 0 1 (25)
Diarrhea Mild 0 1 (25) 1 (25)
Moderate 0 0 0
Nausea Mild 1 (25) 3 (75) 0
Moderate 0 0 0
Vomiting Mild 0 1 (25) 1 (25)
Moderate 0 0 0
Fever Mild 1 (25) 1 (25) 0
Moderate 0 0 1 (25)
Dizziness Mild 2 (50) 2 (50) 0
Moderate 0 0 0
doi:10.1371/journal.pntd.0001285.t006
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particularly in the Nile Delta, and the absence of malaria [28,29].
The prevalence of Fasciola spp. observed in the two study sites (i.e.,
Behera and Alexandria; prevalence 3–4%) was similar to previous
studies in these areas [5,28,30], despite frequent community
treatment programs with triclabendazole.
Our study failed to extend promising findings obtained with the
artemisinins in rats experimentally, and sheep naturally, infected
with F. hepatica [31]. Indeed, we found low CRs (6–35%) when
artemether was given at two different malaria treatment schedules.
Nonetheless, a moderate ERR of 63% was observed following the
6-dose course of artemether. The difference in the ERR between
the two artemether treatment schedules (nil vs. 63%) is striking, yet
difficult to explain. Since the half life of artemether is very short
(,1 h) [32], parasite exposure to the drug might have been
insufficient if the drug is given on a single treatment day. However,
detailed in vitro drug sensitivity and pharmacokinetic studies are
required to further elucidate this issue. It is interesting to note that
the CRs (nil vs. 54%) and ERRs (55% vs. 67%) were higher in
patients classified as lightly infected compared to moderate/heavy
infections in the 6-dose regimen. A similar trend was observed in a
recent study, which assessed the efficacy of an artesunate-sulfalene
plus pyrimethamine combination in S. mansoni-infected school-
aged children in Kenya: significantly higher CRs were observed in
children harboring a light S. mansoni infection compared to
moderate and heavy infections [33].
In the present study, five participants in each of the two studies
were co-infected with Fasciola spp. and S. mansoni. Moderate CRs
were observed against S. mansoni (60%) regardless of the selected
treatment regimen. This finding is in line with previous studies,
which documented low-to-moderate efficacies of an artemisinin
monotherapy in the treatment of chronic infections with
Schistosoma spp. [34–36]. An opposite trend, a CR of 70% and
an ERR of 86% was reported following treatment of Nigerian
children using two doses of artesunate at 6 mg/kg given 2 weeks
apart [37]. In recent years also the effect of ACTs on
schistosomiasis has been studied (for a summary of studies, see
Utzinger et al. (2010) [38]) Overall, a moderate efficacy was
observed using ACTs against the two major schistosome species, S.
mansoni and S. haematobium. Although promising results were
obtained in small exploratory trials with the artemisinins against
schistosomiasis, larger clinical trials could not confirm these
findings, and hence praziquantel remains the drug of choice
[33,38,39].
CRs of 69% and 75% were observed in patients treated with
triclabendazole at 10 mg/kg and 20 mg/kg, respectively. The
observed efficacy is slightly lower than a calculated overall CR of
83% following 10 mg/kg and reported CRs ranging from 93 to
100% following a double dose of triclabendazole [40]. Addition-
ally, a recent study with 10 mg/kg triclabendazole in Egypt
reported a complete cure following triclabendazole (10 mg/kg)
[41]. However, care is indicated in these comparisons because of
the small sample sizes in the current study, although strain
differences in the susceptibility of Fasciola spp. to triclabendazole
might play a role in the somewhat lower efficacies observed here
compared to previous studies. Participants treated with triclaben-
dazole showed a higher incidence of abdominal pain compared to
those treated with artemether, which might be related to the
higher efficacy of triclabendazole (dying worms).
In conclusion, significantly higher CRs and ERRs were
observed with triclabendazole when compared to artemether,
the latter administered following two malaria treatment schedules.
Hence, triclabendazole remains the drug of choice against
fascioliasis. In view of threatening triclabendazole resistance
development, concerted efforts are required, including structure-
activity relationships with the synthetic peroxides in F. hepatica-
infected rats [42]. Combination chemotherapy is also recognized
as a potential strategy for reducing the emergence of drug
resistance [43,44]. Since we have observed synergistic interactions
of combinations of triclabendazole (2.5 mg/kg) plus artemether
(6.25–100 mg/kg) on adult worm burden in F. hepatica-infected
rats [15] further preclinical studies to investigate the efficacy and
safety of an artemether-triclabendazole combination are warrant-
ed. Combination chemotherapy with artemether and triclabenda-
zole might offer an advantage over triclabendazole monotherapy,
in particular in the case of possible future treatment failures with
triclabendazole alone.
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